Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of
heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and
NYHA class II to III.